Vivos Inc. (RDGL)
OTCQB OTCQB Primary 
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance
Vivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data from the partnership showed that patients prefer Vivos CARE as a treatment for obstructive sleep apnea (OSA) nearly two to one over continuous positive airway pressure (CPAP) therapy, the current standard of care treatment.
Vivos Therapeutics announces funding boost
Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.5 million before expenses. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement.
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3
Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses. Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year.
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment
Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.
Vivos Therapeutics raises $4.3 from institutional investors
Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering.
Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment
Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term.
Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships
Vivos Therapeutics (NASDAQ:VVOS) reported solid financial numbers for the second quarter of 2024 with a 19% increase in revenue. The company reported a revenue of $4.1 million compared to the $3.4 million reported in the same quarter of 2023, which the company said was primarily driven by increased sales of Vivos appliances and higher service revenue from Vivos Integrated Provider (VIP) enrollments.
Vivos Therapeutics reports positive results from pilot of provider-based model
Vivos Therapeutics (NASDAQ:VVOS) has announced positive results from a seven-month, multi-site pilot of its new provider-based marketing and distribution model. The medical technology firm on June 12, 2024, unveiled its new marketing and distribution model under which it seeks to drive revenue through partnerships with dentists and sleep treatment providers to offer patients with obstructive sleep apnea (OSA) a range of evidence-based treatment options, including Vivos' FDA-cleared CARE oral medical devices, oral appliances, and additive adjunctive therapies and methods.
Vivos Therapeutics announces strategic alliance and $7.5M investment
Vivos Therapeutics (NASDAQ:VVOS) announced a strategic marketing and distribution alliance with a multi-center sleep testing and treatment operator in Colorado. In a statement, Vivos said that the alliance marks a shift in Vivos' approach to distributing its advanced obstructive sleep apnea (OSA) treatments.
